loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Mechlorethamine

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Mechlorethamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 6,444Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Soligenix Announces Positive Clinical Results for HyBryte™ in CTCL Treatment
    Soligenix Announces Positive Clinical Results for HyBryte™ in CTCL Treatment

    25 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-announces-positive-clinical-results-from-a-comparative-study-evaluating-hybryte-against-valchlor-in-the-treatment-of-cutaneous-t-cell-lymphoma-302181378.html

    PR NEWSWIRE
    25 Jun 2024
    Share Share
    Helsinn Healthcare SA signs exclusive license agreement with Juniper for LEDAGA®
    Helsinn Healthcare SA signs exclusive license agreement with Juniper for LEDAGA®

    01 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/01/2508251/0/en/Helsinn-Healthcare-SA-signs-exclusive-license-agreement-with-Juniper-Biologics-Pte-Ltd-for-LEDAGA-chlormethine-in-Australia-Asia-and-the-Middle-East.html

    GLOBENEWSWIRE
    01 Sep 2022
    Share Share
    Helsinn signs exclusive license deal with Juniper Biologics
    Helsinn signs exclusive license deal with Juniper Biologics

    01 Sep 2022

    // THEPHARMALETTER

    https://www.thepharmaletter.com/article/helsinn-signs-exclusive-license-deal-with-juniper-biologics

    THEPHARMALETTER
    01 Sep 2022
    Share Share
    Recordati & Helsinn Agreement For Commercialization Rights To Ledaga®
    Recordati & Helsinn Agreement For Commercialization Rights To Ledaga®

    18 Dec 2018

    // GLOBENEWSWIRE

    https://globenewswire.com/news-release/2018/12/20/1670176/0/en/RECORDATI-AND-HELSINN-AGREEMENT-FOR-THE-EXCLUSIVE-COMMERCIALIZATION-RIGHTS-TO-LEDAGA.html

    GLOBENEWSWIRE
    18 Dec 2018
    Share Share
    Actelion Registration Ledaga (Chlormethine) Receives Approval In Europe
    Actelion Registration Ledaga (Chlormethine) Receives Approval In Europe

    16 Mar 2017

    // EMA

    https://www.pharmacompass.com/pdf/news/actelion-registration-ledaga-chlormethine-receives-approval-in-europe-1489748556.pdf

    EMA
    16 Mar 2017
    Share Share